Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional) (343339)

US Dept. of Health & Human Services: National Institutes of Health (NIH)

View website    Save this grant

Deadline: Sep 1, 2025

Grant amount: Up to US $5,000,000

Fields of work: Addiction & Substance Use Disorders

Applicant type: Government Entity, Indigenous Group, Nonprofit, For-Profit Business

Funding uses: Research

Location of project: Preferred: United States Other eligible locations: Anywhere in the world

Location of residency: Preferred: United States Other eligible locations: Anywhere in the world


NOTE: Applications will be accepted on a rolling basis, beginning September 2022.  An LOI may be required 30 days prior  to submission.

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of medication for the treatment of Substance Use Disorders (SUDs) by encouraging research applications to support a diverse array of preclinical and/or clinical research projects. The goal is to fund medication studies that will have high impact and quickly yield the necessary results to advance medications closer to FDA approval. It is expected that these U01s will be short-term (funded for up to 3 years) and large (up to $5 million per year) cooperative agreements with close monitoring and significant scientific involvement of NIDA staff. This funding opportunity will enable critical medications development studies that would not be feasible using the traditional R01 activity code.

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.

Other Opportunities from Us Dept. Of Health & Human Services: National Institutes Of Health (Nih)

This page was last reviewed September 02, 2022 and last updated September 02, 2022